Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16174260 | 1.00 | ACHE (0.49) | ACHEMEN1THRBHTTKMT2A | |
| SCHEMBL16174288 | 1.00 | ACHE (0.49) | ACHEMEN1THRBHTTKMT2A | |
| SCHEMBL16174236 | 1.00 | ACHE (0.49) | ACHEMEN1THRBHTTKMT2A | |
| SCHEMBL16174241 | 1.00 | ACHE (0.49) | ACHEMEN1THRBHTTKMT2A | |
| SCHEMBL16174286 | 1.00 | ACHE (0.49) | ACHEMEN1THRBHTTKMT2A | |
| SCHEMBL16174230 | 1.00 | ACHE (0.49) | ACHEMEN1THRBHTTKMT2A | |
| SCHEMBL16174289 | 1.00 | ACHE (0.49) | ACHEMEN1THRBHTTKMT2A | |
| SCHEMBL16174237 | 1.00 | ACHE (0.49) | ACHEMEN1THRBHTTKMT2A | |
| SCHEMBL16174256 | 1.00 | ACHE (0.49) | ACHEMEN1THRBHTTKMT2A | |
| SCHEMBL16174258 | 1.00 | ACHE (0.49) | ACHEMEN1THRBHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | SGMS1, SGMS2, LIPC | ACHE 4109/4885MEN1 608/4885THRB 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.